Targeting TP53 in triple-negative breast cancer: Molecular pathogenesis, therapeutic implications, and emerging pharmacological strategies
- DOI
- 10.1016/j.bulcan.2026.04.016
- Published
- 2026-10
- Container
- Bulletin du Cancer
- Publisher
- Elsevier BV
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1016/j.bulcan.2026.04.016,
title = {Targeting TP53 in triple-negative breast cancer: Molecular pathogenesis, therapeutic implications, and emerging pharmacological strategies},
author = {Barani Karikalan and Ye Htut Linn and Shiueh Lian Mok},
year = {2026},
journal = {Bulletin du Cancer},
doi = {10.1016/j.bulcan.2026.04.016},
url = {https://doi.org/10.1016/j.bulcan.2026.04.016}
}RIS
TY - JOUR TI - Targeting TP53 in triple-negative breast cancer: Molecular pathogenesis, therapeutic implications, and emerging pharmacological strategies AU - Barani Karikalan AU - Ye Htut Linn AU - Shiueh Lian Mok PY - 2026 JO - Bulletin du Cancer DO - 10.1016/j.bulcan.2026.04.016 UR - https://doi.org/10.1016/j.bulcan.2026.04.016 ER -
APA
Karikalan, B., Linn, Y. H., & Mok, S. L. (2026). Targeting TP53 in triple-negative breast cancer: Molecular pathogenesis, therapeutic implications, and emerging pharmacological strategies. Bulletin du Cancer. https://doi.org/10.1016/j.bulcan.2026.04.016
Source records
- crossref · retrieved 2026-09-25T19:35:51.398Z